RecruitingPhase 2NCT06231381
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
Studying Generalized pustular psoriasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Intervention
- HB0034(drug)
- Enrollment
- 33 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2025
Study locations (2)
- Peking University People's Hospital (PKUPH), Beijing, China
- Shanghai Huaota Biopharmaceutical Co., Ltd, Shanghai, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06231381 on ClinicalTrials.gov